SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?

被引：0
|
作者：
Rudofsky, G. [1 ]
Ruessmann, H. -J.
Siegmund, T. [2 ]
机构：
[1] Univ Klinikum Heidelberg, Abt Innere Med & Klin Chem 1, D-69120 Heidelberg, Germany
[2] Stadt Klinikum Munchen GmbH, Klinikum Bogenhausen, Klin Endokrinol Diabetol & Angiol, Munich, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2013年 / 138卷 / 22期
关键词：
blood pressure; type; 2; diabetes; weight reduction; glucosuria; drug therapy; Sodium Glucose Linked Transporter (SGLT); INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; DAPAGLIFLOZIN TREATMENT; ADD-ON; TYPE-2; KIDNEY; METFORMIN; CANAGLIFLOZIN; TRANSPORT; WEIGHT;
D O I：
10.1055/s-0032-1333023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since end of 2012 a new therapeutical approach for the treatment of type 2 diabetes is available in Germany. It relies on the modulation of glucose re-absorption in the kidney by inhibition of so called Sodium Glucose Linked Transporters (SGLT) thereby leading to therapeutical glucosuria. Putting the kidney in the centre of therapeutical approach of glucose regulation is unfamiliar for physicians. Therefore, it is helpful to elucidate the underlying renal mechanisms and to present the advantages and disadvantages of this new therapeutic class. © Georg Thieme Verlag KG, Stuttgart New York.
引用
收藏
页码：1172 / 1177
页数：6
相关论文
共 50 条
  • [1] SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus
    Deshmukh, Aaishwarya B.
    Patel, Maharshi C.
    Mishra, Bharat
    RENAL FAILURE, 2013, 35 (04) : 566 - 572
  • [2] Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
    Pfister, M.
    Whaley, J. M.
    Zhang, L.
    List, J. F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (04) : 621 - 625
  • [3] The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
    Vallon, Volker
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 255 - 270
  • [4] SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
    Ele Ferrannini
    Anna Solini
    Nature Reviews Endocrinology, 2012, 8 : 495 - 502
  • [5] SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
    Ferrannini, Ele
    Solini, Anna
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (08) : 495 - 502
  • [6] SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
    Misra, Monika
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2013, 65 (03) : 317 - 327
  • [7] SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
    Ghosh, Raktim Kumar
    Ghosh, Samhati Mondal
    Chawla, Shalini
    Jasdanwala, Sarfaraz Abdeli
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (04): : 457 - 463
  • [8] SGLT2 inhibition - a novel strategy for diabetes treatment
    Chao, Edward C.
    Henry, Robert R.
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (07) : 551 - 559
  • [9] SGLT2 inhibition — a novel strategy for diabetes treatment
    Edward C. Chao
    Robert R. Henry
    Nature Reviews Drug Discovery, 2010, 9 : 551 - 559
  • [10] SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
    Ito, Hiroyuki
    Shinozaki, Masahiro
    Nishio, Shinya
    Abe, Mariko
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (15) : 2073 - 2084
12345